TNF and atherosclerosis: Moreover, targeted therapies, such as tumor necrosis factor α (TNF-α) inhibitors may dampen secondary inflammatory atherosclerosis and may prevent major CV events (MACE), particularly in anti-TNF-responders [1,12,13,14,15].